Takeda and BioMotiv in strategic partnership, including investment

25 September 2014
takeda-logo-big

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has made a strategic investment in USA-based BioMotiv, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Additionally, the companies have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations.

The initial investment is around $25million over five years. This investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of immunology and inflammation, and cardio-metabolic diseases.

Launched in 2012, The Harrington Project for Discovery & Development is a $250 million national initiative, comprising the not-for-profit Harrington Discovery Institute and BioMotiv, a for-profit therapeutic accelerator.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical